Brasilia (Reuters)-Brazilian health regulator Ambiza said late Saturday that it had approved the import of two million COVID-19 vaccines developed by AstraZeneca (NASDAQ :) and Oxford University, but the use of jabs is still In an unapproved country.
Ambiza said Thursday that it had approved an import request from the federal biomedical center Fiocrus.
By importing the dose before approval, regulators said it would allow Amvisa to begin vaccination as soon as it approved its use. Brazil has not yet approved the vaccine.
Fiocruz will apply for an emergency use of the vaccine by Wednesday, its president, Nísia Trindade, said last week.
Brazil has recorded the second most deadly outbreak of COVID-19 after the United States. The largest country in South America has the third highest number of cases of coronavirus, with more than 7.7 million registered by the Ministry of Health after the United States and India.
Fusion media Alternatively, anyone involved with Fusion Media will not be liable for any loss or damage resulting from relying on the data, quotes, charts, trading signals and other information contained on this website. Please be fully informed about the risks and costs associated with trading in financial markets. This is one of the most risky forms of investment possible.
Brazil imports 2 million doses of AstraZeneca vaccine, but has not yet been approved for use by Reuters
https://www.investing.com/news/stock-market-news/brazil-to-import-2-million-astrazeneca-vaccine-doses-not-yet-approved-for-use-2378761 Brazil imports 2 million doses of AstraZeneca vaccine, but has not yet been approved for use by Reuters